STAFF BOARD
Article
CHAIRMAN
Virginia Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Jaime E. Poquet Jornet
MARKETING MANAGER
EDITORIAL BOARD
Ramón Jódar Masanés
Lluís Campins Bernadas
Tomás Casasín Edo
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 22 - Issue 3, July-September 2020
SHORT REPORTS
RE-INITIATION OF TREATMENT WITH SARGRAMOSTIM IN A PATIENT WITH PULMONARY ALVEOLAR PROTEINOSIS
BOULLOSA LALE SILVIA, GONZÁLEZ FREIRE LARA, VEIGA VILLAVERDE ANA BELÉN, CRESPO DIZ CARLOS


Pulmonary alveolar proteinosis (PAP) is an autoimmune lung disease characterized by the accumulation of lipoprotein material derived from the pulmonary surfactant present inside pulmonary alveoli. This causes deterioration of gas exchange and triggers progressive respiratory failure. Here we present the case of a woman diagnosed
with PAP who had already been treated with granulocyte and macrophage colony stimulating factor (GM-CSF). After 49 weeks without treatment, a progressive clinical deterioration and worsening of her respiratory parameters began to present. Re-treatment with inhaled sargramostim (125 μg/12 h, every other week) was initiated. Her clinical picture started to improve, and after 56 weeks of treatment, her dose was reduced to 125 μg/24 h on alternate weeks. At the time of completing this study two and a half years had elapsed since the reduction of her dose. The clinical
evolution of the patient remains positive, her respiratory parameters are stable, and she is continuing with the same dosage.

PULMONARY ALVEOLAR PROTEINOSIS – RE-TREATMENT – SARGRAMOSTIM



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25